Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Xiao, Meng; Huang, Jing-jing; Zhang, Ge; Yang, Wen-hang; Kong, Fanrong; Kudinha, Timothy; Xu, Ying-chun

doi:10.1186/s12866-020-02019-8

Table 3 Activity of omadacycline and comparator agents against a range of bacterial pathogens from 25 teaching hospitals in China

From: Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Antimicrobial agent by organism or organism group (no. tested)	MIC₅₀ (mg/L)	MIC₉₀ (mg/L)	S (%)	R (%)	NS (%)
Staphylococcus aureus (197)
Omadacycline	0.12	0.25	98.5 ^a	0.5 ^a
Tigecycline	0.12	0.25	99.5		0.5
Tetracycline	16	64	36.0	58.9
Clindamycin	0.12	8	64.5	34.0
Daptomycin	0.5	1	99.0		1.0
Gentamicin	0.5	64	59.9	33.5
Levofloxacin	4	8	48.2	50.8
Linezolid	1	2	99.5	0.5
Oxacillin	2	8	50.8	49.2
Trimethoprim-sulfamethoxazole	0.25	1	96.4	3.6
Vancomycin	1	1	100.0	0.0
Enterococcus spp. (25)
Omadacycline	0.03	0.12	100.0 ^b	0.0 ^b
Tigecycline	0.12	0.25	100.0		0.0
Minocycline	16	16	40.0	52.0
Tetracycline	64	64	24.0	76.0
Daptomycin	1	2	100.0	0.0
Moxifloxacin	8	8	16.0	84.0
Linezolid	2	2	100.0	0.0
Vancomycin	1	2	96.0	4.0
Streptococcus pneumoniae (59)
Omadacycline	0.06	0.06	96.6	0.0
Tigecycline	<0.03	0.03	94.9		5.1
Tetracycline	32	64	6.8	89.8
Ceftriaxone	0.25	4	81.4	11.9
Erythromycin	2	2	22.0	76.3
Levofloxacin	1	1	98.3	1.7
Linezolid	1	1	100.0	0.0
Penicillin	0.12	4	89.8	1.7
Enterobacterales (651)
Omadacycline	2	8	81.7 ^c	8.6 ^c
Tigecycline ^d	0.5	2	91.6 ^d	1.1 ^d
Minocycline	4	32	34.6		56.2
Tetracycline	64	64	33.9	61.6
Amikacin	4	16	85.7	8.6
Ciprofloxacin	2	64	57.8	35.6
Ceftazidime	64	64	42.1	56.2
Ceftriaxone	0.5	2	85.3	8.8
Imipenem	1	4	40.7	52.7
Piperacillin-tazobactam	4	128	70.5	24.1
Escherichia coli (260)
Omadacycline	1	4	92.3	4.6
Tigecycline ^d	0.25	1	94.6 ^d	0.4 ^d
Minocycline	8	21	0.0	99.6
Tetracycline	64	64	14.6	85.0
Aztreonam	8	32	46.2	49.6
Amikacin	4	8	80.0	7.7
Ciprofloxacin	4	4	29.2	63.5
Ceftazidime	2	64	59.2	32.7
Ceftriaxone	64	64	41.2	58.5
Imipenem	0.5	0.5	96.2	2.7
Piperacillin-tazobactam	4	128	81.9	13.5
Klebsiella pneumoniae (271)
Omadacycline	2	16	70.5	13.3
Tigecycline ^d	1	4	86.7 ^d	2.2 ^d
Minocycline	4	64	51.3	32.5
Tetracycline	8	64	46.5	46.9
Aztreonam	16	32	45.4	52.8
Amikacin	4	64	86.7	12.5
Ciprofloxacin	0.5	4	43.9	49.8
Ceftazidime	4	64	52.8	42.1
Ceftriaxone	64	64	38.7	59.8
Imipenem	0.5	32	81.9	14.4
Piperacillin-tazobactam	4	128	63.8	31.7
Acinetobacter baumannii (198)
Omadacycline	4	16
Tigecycline	2	8
Minocycline	8	16	45.5	28.3
Tetracycline	64	64	16.2	81.3
Amikacin	64	64	29.8	69.7
Ciprofloxacin	4	4	21.2	76.8
Cefepime	64	256	19.7	75.8
Imipenem	32	64	24.7	75.3
Piperacillin-tazobactam	128	128	23.2	75.3
Pseudomonas aeruginosa (30)
Omadacycline	32	32
Tigecycline ^e	8	16
Minocycline	8	32
Tetracycline ^e	32	64	0.0	100.0 ^e
Amikacin	4	8	93.3	6.7
Ciprofloxacin	0.25	4	73.3	23.3
Cefepime	1	64	73.3	20.0
Imipenem	1	16	80.0	20.0
Piperacillin-tazobactam	8	128	63.3	20.0

^aUsing FDA identified breakpoints for ABSSSIs
^bUsing FDA identified breakpoints for Enterococcus faecalis
^cUsing FDA identified breakpoints for Klebsiella pneumoniae and Enterobacter cloacae
^dUsing EUCAST clinical breakpoints for tigecycline
^eTigecycline and tetracycline are inherent resistant against Pseudomonas aeruginosa ccording to CLSI document M100ED29E

Back to article page

ISSN: 1471-2180

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Microbiology

Contact us